当前位置： SCI文献检索 > INTERNATIONAL JOURNAL OF HEMATOLOGY期刊下所有文献 > CD34+ progenitor cell transplantation from two HLA-mismatched healthy fathers to two infants with severe aplastic anemia.

CD34+ progenitor cell transplantation from two HLA-mismatched healthy fathers to two infants with severe aplastic anemia.

Abstract：

:Pluripotent stem cells of hematopoiesis are included among CD34+ cells in the blood and bone marrow. After granulocyte-colony stimulating factor (G-CSF) mobilization, 1-2% of the mononuclear cells in the blood are CD34+ cells, which can be obtained by leukapheresis. We performed CD34+ progenitor cell transplantation in two children with severe aplastic anemia (SAA) who lacked HLA-matched donors. The donors were treated with G-CSF, 600 micrograms/body/day subcutaneously, for 4-5 days. CD34+ cell selection was performed from the apheresis concentrate with mouse anti-CD34 antibody 9C5 and magnet beads coated with sheep anti-mouse IgG1. After the transplantation, the patients received tacrolimus to prevent graft-versus-host disease (GVHD). G-CSF was given to both patients. A mean number of 4.96 x 10(6) CD34+ cells per kilogram of body weight were transplanted. The hematopoietic recovery after the CD34+ cell transplantation was rapid, except for platelets, and acute GVHD was less than or equal to grade I. Case 1, who demonstrated mixed chimerism, anemia and thrombocytopenia after the graft, received a second transplant with intensified preconditioning, and now sustains complete and stable hematopoiesis after a follow-up of 314 days posttransplant. Although Case 2 showed early rejection and received a second transplant, sustained engraftment was never achieved. However, the patient's own hematopoiesis appeared. For SAA patients who do not have HLA-matched donors, this type of approach seems to be a feasible and useful method. However, an intensified preconditioning regimen to overcome the high likelihood of rejection should be employed.

journal_name

Int J Hematol

journal_title

International journal of hematology

authors

Yasui M,Park YD,Okamura T,Chayama K,Yoshimoto T,Inoue M,Yagi K,Kawa K

doi

10.1016/s0925-5710(97)00088-1

subject

Has Abstract

pub_date

1998-01-01 00:00:00

pages

15-22

issue

1

eissn

0925-5710

issn

1865-3774

pii

S0925571097000881

journal_volume

67

pub_type

杂志文章

相关文献

INTERNATIONAL JOURNAL OF HEMATOLOGY文献大全
  • Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population.

    abstract：:Immune reconstitution affects clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT), and it has been suggested that lymphocyte recovery affects survival after HSCT. However, few studies have examined lymphocyte recovery in Asian patients who received mycophenolate mofetil (MMF) prophylaxis ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-018-2437-z

    authors： Kurata K,Yakushijin K,Mizuno I,Gomyo H,Okamura A,Ichikawa H,Sakai R,Mizutani Y,Kakiuchi S,Miyata Y,Kitao A,Sanada Y,Inui Y,Uryu K,Kawamoto S,Sugimoto T,Yamamoto K,Ito M,Matsuoka H,Murayama T,Minami H

    更新日期：2018-07-01 00:00:00

  • Signal transduction in macrophages: negative regulation for macrophage colony-stimulating factor receptor signaling.

    abstract：:The receptor for macrophage colony-stimulating factor (M-CSF) is expressed in monocytes/macrophages and their progenitor cells and stimulates both the growth and development of the blood-cell lineage. Although the specific components positively regulating M-CSF receptor signaling have been relatively well defined, it ...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02982712

    authors： Suzu S,Motoyoshi K

    更新日期：2002-07-01 00:00:00

  • Hypocalcemic heart failure in thalassemic patients.

    abstract：:Hypocalcemic cardiomyopathy in primary or secondary hypoparathyroidism is usually refractory to conventional treatment of cardiac failure. We report the case of a thalassemic patient with severe cardiac failure that might have been attributed to several factors, such as hemosiderosis, hypomagnesemia, and hypocalcemia,...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.E0532

    authors： Tsironi M,Korovesis K,Farmakis D,Deftereos S,Aessopos A

    更新日期：2006-05-01 00:00:00

  • Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency.

    abstract：:Patients with severe congenital protein (P)C deficiency require long-term anticoagulant management. Recombinant PC concentrates for prophylactic use are not available in Japan; prothrombin complex concentrates (PCC), containing factors (F)II, VII, IX, X, and PC (PPSB-HT®), have been used 'off-label' in a few patients....

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-019-02645-7

    authors： Ogiwara K,Nogami K,Mizumachi K,Nakagawa T,Noda N,Ohga S,Shima M

    更新日期：2019-06-01 00:00:00

  • Expression of activated molecules on CD5(+)B lymphocytes in autoimmune hemolytic anemia.

    abstract：:To investigate the expression of activation molecules on CD5(+)B lymphocytes in peripheral blood of autoimmune hemolytic anemia (AIHA)/Evans patients. The expression of CD80, CD86, and CD69 on CD5(+)B lymphocytes was detected using flow cytometry in 30 AIHA/Evans patients, 18 normal controls (NC) and nine chronic lymp...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-016-1964-8

    authors： Zhu H,Xu W,Liu H,Wang H,Fu R,Wu Y,Qu W,Wang G,Guan J,Song J,Xing L,Shao Z

    更新日期：2016-05-01 00:00:00

  • Presence of the entire coding region of GP IV mRNA in Nak(a)-negative platelets.

    abstract：:It has been reported that Nak(a)-negative platelets lack GP IV. To examine the GP IV genetic defects in Nak(a)-negative platelets, we studied four unrelated Nak(a)-negative subjects by amplifying their GP IV cDNA, which were synthesized from platelet mRNA using the reverse transcriptase/polymerase chain reaction (RT/P...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：

    authors： Kashiwagi H,Honda S,Take H,Mizutani H,Imai Y,Furubayashi T,Tomiyama Y,Kurata Y,Yonezawa T

    更新日期：1993-04-01 00:00:00

  • Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.

    abstract：:We present a patient with refractory multiple myeloma who showed a good response to a combination therapy with oral melphalan, dexamethasone, and thalidomide (MDT). A 48-year-old woman with myeloma refractory to thalidomide, dexamethasone, and clarithromycin received 6 mg melphalan for 4 days every 6 weeks in combinat...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.06164

    authors： Asou N,Izuno Y,Okubo T,Ide K,Ueno H,Kawakita M,Mitsuya H,Hata H

    更新日期：2007-07-01 00:00:00

  • Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.

    abstract：:Platelet activation, impairment of fibrinolysis, activation of the coagulation pathway, and dyslipidemia are important factors in the pathogenesis and progression of ischemic heart disease, and patients generally need to use an antiplatelet agent. Lipid-lowering cerivastatin, a novel 3-hydroxy-3-methylglutaryl coenzym...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF02982799

    authors： Ural AU,Yilmaz MI,Avcu F,Yalcin A

    更新日期：2002-10-01 00:00:00

  • Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

    abstract：:High-dose melphalan followed by autologous hematopoietic stem cell transplantation (ASCT) is a standard treatment for younger myeloma patients. However, the correlation between its toxicity and renal impairment is not clear. We analyzed this relationship, focusing on estimated glomerular filtration rate (eGFR) as an i...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s12185-018-2507-2

    authors： Tamaki M,Nakasone H,Gomyo A,Hayakawa J,Akahoshi Y,Harada N,Kusuda M,Ishihara Y,Kawamura K,Tanihara A,Sato M,Terasako-Saito K,Kameda K,Wada H,Kikuchi M,Kimura SI,Kako S,Kanda Y

    更新日期：2018-10-01 00:00:00

  • Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy.

    abstract：:To examine the effects and optimal dose of danazol on idiopathic thrombocytopenic purpura (ITP), we administered a low-medium dose to 14 patients with this disease. A low-medium dose of danazol was effective in maintaining the platelet count at a high level, even after the dose of prednisolone was reduced. A low-mediu...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章

    doi：

    authors： Kondo H,Iseki T,Goto S,Takaso T,Ohto M,Okuda K

    更新日期：1992-06-01 00:00:00

  • Characterization of hereditary red blood cell membranopathies using combined targeted next-generation sequencing and osmotic gradient ektacytometry.

    abstract：:Hereditary red blood cell (RBC) membranopathies are characterized by mutations in genes encoding skeletal proteins that alter the membrane complex structure. Hereditary spherocytosis (HS) is the most common inherited RBC membranopathy leading to hereditary hemolytic anemia with a worldwide distribution and an estimate...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-020-03010-9

    authors： Vives-Corrons JL,Krishnevskaya E,Rodriguez IH,Ancochea A

    更新日期：2020-10-19 00:00:00

  • Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.

    abstract：:The introduction of all-trans retinoic acid (ATRA) has made acute promyelocytic leukemia (APL) a curable disease; however, early death prior to the completion of treatment remains a problem. In quantitative evaluation of response to ATRA treatment, lymphocytes must be excluded as they do not originally have t(15;17). ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-018-2472-9

    authors： Sato K,Sakai H,Saiki Y,Uchida A,Uemura Y,Yokoi S,Tsuruoka Y,Nishio Y,Matsunawa M,Suzuki Y,Isobe Y,Kato M,Tomita N,Inoue Y,Miura I

    更新日期：2018-09-01 00:00:00

  • Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.

    abstract：:Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma characterized by production of the immunoglobulin M (IgM) monoclonal protein. Commonly involved sites are the bone marrow, lymph nodes, and spleen. Lymphoplasmacytic infiltration of the central nervous system (CNS), in contrast, is referred to as Bing-Neel ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-013-1372-2

    authors： Morita K,Yoshimi A,Masuda A,Ichikawa M,Yatomi Y,Kurokawa M

    更新日期：2013-08-01 00:00:00

  • Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.

    abstract：:The majority of adults diagnosed with acute myeloid leukemia (AML) display acquired cytogenetic aberrations at presentation. Numerous recurring chromosomal abnormalities have been and continue to be identified in AML. In many instances, genes altered by these aberrations have been cloned, providing insights into the m...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：

    authors： Mrózek K,Heinonen K,Bloomfield CD

    更新日期：2000-10-01 00:00:00

  • Evi-1 as a critical regulator of leukemic cells.

    abstract：:Ecotropic viral integration site-1 (EVI-1) has been recognized as one of the dominant oncogenes associated with murine and human myeloid leukemia. Recent clinical studies demonstrated that high EVI-1 expression was an independent negative prognostic indicator of survival in leukemia patients. In addition, gene-targeti...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-010-0618-5

    authors： Goyama S,Kurokawa M

    更新日期：2010-06-01 00:00:00

  • Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma.

    abstract：:A pilot phase I/II study was conducted as a single-institute trial for evaluation of the feasibility and efficacy of a new salvage chemotherapy, CHASE, for patients with refractory or relapsed lymphoma . The CHASE regimen, consisting of cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone, was administ...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF02986620

    authors： Ogura M,Kagami Y,Taji H,Suzuki R,Miura K,Takeuchi T,Morishima Y

    更新日期：2003-06-01 00:00:00

  • Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP.

    abstract：:The objective of present study was to compare the prognosis of diffuse large B-cell lymphoma (DLBCL) with Waldeyer's ring involvement (WR-DLBCL) to that of nodal DLBCL (N-DLBCL) without WR involvement. Between July 2004 and October 2009, medical records and metabolic tumor volume (MTV) measured by 2-[fluorine-18]-fluo...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-013-1282-3

    authors： Oh MY,Chung JS,Song MK,Shin HJ,Lee HS,Lee SM,Lee GW,Lee SE

    更新日期：2013-03-01 00:00:00

  • T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

    abstract：:Posttransplant lymphoproliferative disorder (PTLD) after allogeneic hematopoietic cell transplantation (HCT) is usually donor derived, associated with Epstein-Barr virus (EBV), and of B-cell origin. T-cell PTLD (T-PTLD) after allogeneic HCT is extremely rare. Four of 1015 (0.39%) allogeneic HCT patients were diagnosed...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-020-02890-1

    authors： Kuno M,Ito A,Maeshima AM,Taniguchi H,Tanaka T,Inamoto Y,Kurosawa S,Kim SW,Fukuda T

    更新日期：2020-08-01 00:00:00

  • Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.

    abstract：:We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT). We retrospectively examined 127 patients [acute myeloid leukemi...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-018-02567-w

    authors： Minakata D,Fujiwara SI,Ikeda T,Kawaguchi SI,Toda Y,Ito S,Ochi SI,Nagayama T,Mashima K,Umino K,Nakano H,Yamasaki R,Morita K,Kawasaki Y,Sugimoto M,Yamamoto C,Ashizawa M,Hatano K,Sato K,Oh I,Ohmine K,Muroi K,Ohmo

    更新日期：2019-02-01 00:00:00

  • Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.

    abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) and tyrosine kinase inhibitor have revolutionized the treatment of patients with chronic myeloid leukemia (CML). In this study, the clinical impact of HSCT and imatinib mesylate (IM) was retrospectively analyzed in 28 children with CML treated in our institutes...

    journal_title：International journal of hematology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s12185-010-0764-9

    authors： Muramatsu H,Takahashi Y,Sakaguchi H,Shimada A,Nishio N,Hama A,Doisaki S,Yagasaki H,Matsumoto K,Kato K,Kojima S

    更新日期：2011-02-01 00:00:00

  • Involvement of the BCL3 gene in two patients with chronic lymphocytic leukemia.

    abstract：:The t(14;19)(q32;q13) is a recurring translocation found in some patients with chronic lymphocytic leukemia (CLL), and the t(14;19) juxtaposes the BCL3 gene on chromosome 19 with the immunoglobulin heavy chain gene (IGH) locus on chromosome 14. Genomic DNAs from 49 patients with chronic B-cell leukemia and the related...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：

    authors： Yabumoto K,Ohno H,Doi S,Edamura S,Arita Y,Akasaka T,Matsumoto J,Kadowaki N,Fukuhara S,Okuma M

    更新日期：1994-04-01 00:00:00

  • Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients.

    abstract：:There is an ongoing search for potential biomarkers for acute myeloid leukemia (AML) patients using metabolic analysis. However, only few studies to date have focused on bone marrow samples or a specific subtype of AML. In the present study, we used gas chromatography time-of-flight mass spectrometry of plasma and bon...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-020-02836-7

    authors： Zhou X,Zheng M,Wang Q,Aa J,Cao B,Li J

    更新日期：2020-06-01 00:00:00

  • JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.

    abstract：:Myeloproliferative neoplasms (MPNs) constitute a group of phenotypically diverse chronic myeloid malignancies, characterized by clonal hematopoiesis and excessive production of terminally differentiated myeloid blood cells. The MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibro...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s12185-013-1295-y

    authors： Tanaka M,Yujiri T,Ito S,Okayama N,Takahashi T,Shinohara K,Azuno Y,Nawata R,Hinoda Y,Tanizawa Y

    更新日期：2013-03-01 00:00:00

  • Biology and clinical application of CAR T cells for B cell malignancies.

    abstract：:Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy. We review here the T cell bi...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-016-2039-6

    authors： Davila ML,Sadelain M

    更新日期：2016-07-01 00:00:00

  • Transforming growth factor beta, pleiotropic regulator of hematopoietic stem cells: potential physiological and clinical relevance.

    abstract：:Transforming growth factor beta (TGF-beta) is a pleiotropic regulator of all stages of hematopoieis. Depending on the differentiation stage of the target cell, the local environment, and the concentration of TGF-beta, TGF-beta can be proproliferative or antiproliferative, proapoptotic or antiapoptotic, and/or prodiffe...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02982545

    authors： Ruscetti FW,Bartelmez SH

    更新日期：2001-07-01 00:00:00

  • Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase

    abstract：:Rapid vitamin K antagonist (VKA) reversal is required in patients experiencing major bleeding or requiring urgent surgery. Four-factor prothrombin complex concentrate (4F-PCC; Beriplex®/Kcentra®) was shown in two large randomized controlled, international phase 3b trials to be an effective alternative to plasma for ur...

    journal_title：International journal of hematology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s12185-017-2311-4

    authors： Kushimoto S,Fukuoka T,Kimura A,Toyoda K,Brainsky A,Harman A,Chung T,Yasaka M

    更新日期：2017-12-01 00:00:00

  • Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals.

    abstract：:Immune thrombocytopenia (ITP) is an autoimmune disorder described as autoantibody-mediated platelet deterioration. Platelets with affiliated IgG are targeted for exploitation by Fc receptor-mediated phagocytic cellular material within the reticuloendothelial system. The objective of this research is to investigate the...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s12185-012-1187-6

    authors： Wu Z,Zhou J,Prsoon P,Wei X,Liu X,Peng B

    更新日期：2012-11-01 00:00:00

  • Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.

    abstract：:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of myeloid neoplasm. Clonal evolution in the development of BPDCN remains to be elucidated. In the present study, we examined clonal evolution in a case of BPDCN by analyzing the distribution of gene mutations in tumor cells and non-tumor blood cel...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-018-2461-z

    authors： Suma S,Sakata-Yanagimoto M,Nguyen TB,Hattori K,Sato T,Noguchi M,Nannya Y,Ogawa S,Watanabe R,Fujimoto M,Nakamura N,Kusakabe M,Nishikii H,Kato T,Chiba S

    更新日期：2018-10-01 00:00:00

  • Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

    abstract：:We evaluated the efficacy and safety of switching to nilotinib in CML-CP patients who had achieved MMR with continuous detectable BCR-ABL1 transcript levels after long-term imatinib treatment. Patients who had achieved MMR, but not deep molecular response (DMR), after > 18 months from the initiation of imatinib receiv...

    journal_title：International journal of hematology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s12185-018-2401-y

    authors： Ishikawa J,Matsumura I,Kawaguchi T,Kuroda J,Nakamae H,Miyamoto T,Matsuoka KI,Shibayama H,Hino M,Hirase C,Kamimura T,Shimose T,Akashi K,Kanakura Y

    更新日期：2018-05-01 00:00:00

  • An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).

    abstract：:The heterogeneity of bone marrow plasmacytosis is clearly analyzed by multicolor staining with anti-CD38 antibody. To date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.05112

    authors： Otsuyama K,Asaoku H,Kawano MM

    更新日期：2006-01-01 00:00:00